The abstract is read at the publisher; the summary is JClub's.
Biosimilar entry for bevacizumab, rituximab, and trastuzumab in US oncology is linked to a 3.8% annual ASP decline and falling reference market share.
- Why it matters: Payers and patients need evidence on how biosimilar competition changes pricing and utilization, especially after multiple anticancer biologics gained biosimilar options in the US.
- What they did: A retrospective cohort used Merative MarketScan commercial and Medicare data (July 2019–December 2024) to compare payer and out-of-pocket costs by 12-month use patterns across 14,655 patients.
- The result: Reference ASP fell 3.8% annually and reference market share dropped 30% annually (commercial) and 31.5% (Medicare Part B), while exclusive biosimilar users had $3820 lower mean monthly payer costs and $39.50 lower mean monthly out-of-pocket costs.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.